Access to Medicines
CHAI works with governments and companies around the world to fundamentally change the economics of global health. By securing lower prices for key commodities and improving laboratories in the developing world, we are helping patients’ access the treatment and care they need.
Increasing Access to Medicines and Diagnostics
CHAI works to accelerate patient access to the most effective, high-quality health products at affordable yet sustainable prices. CHAI’s approach involves coordinated and intensive engagement on both the demand and supply sides of the market.
On the demand side, CHAI works with governments to build and consolidate demand around optimal products in terms of efficacy, formulation, quality, and price. On the supply side, CHAI works with manufacturers to reduce the costs of production, enhance competition, encourage adoption of stringent quality standards, optimize product design, and accelerate the entry
and uptake of new and better products.
CHAI believes that patients should not just have access to inexpensive drugs and diagnostics, but that those treatments should be the best drugs and diagnostics available in the market. CHAI has had success in making the preferred treatments for HIV and malaria in developed markets accessible and affordable in low and middle-income countries. CHAI also collaborates with partners in developing newer, better products, including new diagnostics and new drugs, such as more convenient fixed dose combination (FDC) products to make adherence to treatment easier.
The scope of health commodity markets covered by the program has grown in recent years, and now includes medicines and diagnostics for HIV, tuberculosis and malaria, as well as vaccines and contraceptives. Specific accomplishments achieved globally and in country are captured in the sections above. CHAI’s Access to Medicines Program continues to explore access opportunities in other markets and disease areas where a transformational impact can be made.